

P.O. Box 747
Falls Church, Virginia 22040-0747
Phone: (703) 205-8000
Fax: (703) 205-8050
(703) 698-8590 (GIV)

Birch, Stewart, Kolasch & Birch, LLP

Fax

URGENT

To:	Examiner Khare	From:	Marc S. Weiner
Fax:	571-273-0653	Date:	June 7, 2004
Phone:		Pages:	(including cover sheet)
Your Ref.:		Our Ref.:	2059-0106P
Re:	Harold G. BROWN et al.; Application No. 09/880,907	CC:	

☒ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution, or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (703) 205-8000, and send the original transmission to us by return mail at the address above.

Comments: Please confirm receipt. Thank you.

OPIC
OFFICE DE LA PROPRIÉTÉ
INTELLECTUELLE DU CANADA



Ottawa Hull K1A 0G9

CIPO
CANADIAN INTELLECTUAL
PROPERTY OFFICE

(21)	(A1)	2,156,013
(22)		1995/08/14
(43)		1997/02/15

(51) Int.Cl. ⁶ A61K 31/725

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) Modulation of Cellular Activity

(72) Asculai, Samuel Simon - Canada ;

(71) Hyal Pharmaceutical Corporation - Canada ;

(57) 18 Claims

Notice: This application is as filed and may therefore contain an incomplete specification.



Industrie Canada Industry Canada

OPIC - CIPO 191

Canada

2156013

ABSTRACT

A method for the modulation of cellular activity of tissue and cells expressing a high affinity cell-surface receptor for hyaluronic acid, for example an adhesion molecule (for example, ICAM-1, HARLEC and CD44) and a Regulatory molecule (for example, RHAMM) of a human is provided the method comprising the administration of a non-toxic effective amount of a form of hyaluronic acid (for example, hyaluronic acid, a salt thereof, [for example, sodium hyaluronate having a molecular weight less than 750,000 daltons, [for example, 225,000 daltons], for example from Hyal Pharmaceutical Corporation within the range of 150,000-225,000 daltons and those disclosed in U.S. Patent Application 08/143983, molecular weight fractions of a form of sodium hyaluronate (for example, fractions disclosed in Canadian Letters Patent 1205031 (to Fidia) such as those from 50,000-100,000 daltons, 250,000-350,000 daltons and 500,000-730,000 daltons, or other fractions, homologues, analogues, derivatives, complexes, esters, fragments and/or sub units of hyaluronic acid and/or combinations thereof) and/or hyaluronic acid mimicking molecules to a human to modulate cellular activity of tissues and/or cells expressing a high affinity cell-surface receptor for hyaluronic acid, for example, an adhesion molecule and a Regulatory molecule in the human body, in a pharmaceutical excipient tolerable by the human (for example, sterile water).